Form 4: Amgen Executive Nancy Grygiel Reports Equity Transactions

Amgen SVP and CCO Nancy A. Grygiel disclosed the acquisition of restricted stock units and stock options as part of an equity incentive plan.

Summary

• Nancy A. Grygiel, SVP & CCO of Amgen Inc., received a grant of 485 Restricted Stock Units (RSUs) on 05/05/2026.
• The reporting person was granted 3,167 non-qualified stock options with an exercise price of $329.59 on 05/05/2026.
• A total of 76 shares were withheld on 05/06/2026 to satisfy tax obligations related to equity vesting.
• Following these transactions, the reporting person holds 7,418 shares directly and 106.1864 shares indirectly via a 401(k) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure regarding standard executive compensation and does not signal a change in company outlook.

Positives

• Equity grants align executive interests with long-term shareholder value creation.
• The reporting person maintains a significant direct ownership stake of 7,418 shares.

Negatives

• The withholding of 76 shares for tax purposes represents a minor reduction in direct holdings.

Risks

• Future value of stock options is dependent on the company's share price exceeding the $329.59 exercise price.
• Vesting of RSUs and options is subject to continued employment and the terms of the 2009 Equity Incentive Plan.

Future Outlook

The equity grants vest in four equal annual installments of 25% each, beginning on May 5, 2027, indicating a long-term retention strategy for the executive.

Industry Context

StockSavvy.ai notes that routine equity grants to C-suite executives are standard practice in the biopharmaceutical industry to ensure leadership retention and alignment with long-term corporate performance goals.

Comparison to Industry Standards

• The use of four-year vesting schedules for RSUs and options is consistent with standard corporate governance practices among large-cap pharmaceutical companies like Pfizer, Merck, and Bristol Myers Squibb.

Stakeholder Impact

• Minimal impact on shareholders as these are standard compensatory equity grants.

Next Steps

• Vesting of the first 25% installment of RSUs and stock options on 05/05/2027.

Key Dates

Keywords

Amgen, AMGN, Insider Trading, Form 4, Equity Incentive Plan, Stock Options, Restricted Stock Units